With respect to sex differences in CKD, women with CKD have a lower risk of CKD progression,9 cardiovascular events,10 and mortality compared with men.10 Given sex differences in the efficacy and safety of several commonly prescribed cardiovascular medications, including angiotensin-converting enzyme (ACE) inhibitors and statins,11 it is essential to understand whether sex modifies the effects of dapagliflozin in CKD. Here, ACE is linked to chronic kidney disease.